Literature DB >> 9755114

Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress.

E N Atochina1, I V Balyasnikova, S M Danilov, D N Granger, A B Fisher, V R Muzykantov.   

Abstract

The pulmonary endothelium is susceptible to oxidative insults. Catalase conjugated with monoclonal antibodies (MAbs) against endothelial surface antigens, angiotensin-converting enzyme (MAb 9B9) or intercellular adhesion molecule-1 (MAb 1A29), accumulates in the lungs after systemic injection in rats (V. Muzykantov, E. Atochina, H. Ischiropoulos, S. Danilov, and A. Fisher. Proc. Natl. Acad. Sci. USA 93: 5213-5218, 1996). The present study characterizes the augmentation of antioxidant defense by these antibody-catalase conjugates in isolated rat lungs perfused for 1 h with catalase conjugated with either MAb 9B9, MAb 1A29, or control mouse IgG. Approximately 20% of the injected dose of Ab-125I-catalase accumulated in the perfused rat lungs (vs. <5% for IgG-125I-catalase). After elimination of nonbound material, the lungs were perfused further for 1 h with 5 mM hydrogen peroxide (H2O2). H2O2 induced an elevation in tracheal and pulmonary arterial pressures (126 +/- 7 and 132 +/- 5%, respectively, of the control level), lung wet-to-dry weight ratio (7.1 +/- 0.4 vs. 6.0 +/- 0.01 in the control lungs), and ACE release into the perfusate (436 +/- 20 vs. 75 +/- 7 mU in the control perfusates). Both MAb 9B9-catalase and MAb 1A29-catalase significantly attenuated the H2O2-induced elevation in 1) angiotensin-converting enzyme release to the perfusate (215 +/- 14 and 217 +/- 38 mU, respectively), 2) lung wet-to-dry ratio (6.25 +/- 0.1 and 6.3 +/- 0.3, respectively), 3) tracheal pressure (94 +/- 4 and 101 +/- 4%, respectively, of the control level), and 4) pulmonary arterial pressure (103 +/- 3 and 104 +/- 7%, respectively, of the control level). Nonconjugated catalase, nonconjugated antibodies, nonspecific IgG, and IgG-catalase conjugate had no protective effect, thus confirming the specificity of the effect of MAb-catalase. These results support a strategy of catalase immunotargeting for protection against pulmonary oxidative injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755114     DOI: 10.1152/ajplung.1998.275.4.L806

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  24 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  Endothelial targeting of antibody-decorated polymeric filomicelles.

Authors:  Vladimir V Shuvaev; Marc A Ilies; Eric Simone; Sergei Zaitsev; Younghoon Kim; Shenshen Cai; Abdullah Mahmud; Thomas Dziubla; Silvia Muro; Dennis E Discher; Vladimir R Muzykantov
Journal:  ACS Nano       Date:  2011-08-23       Impact factor: 15.881

Review 3.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

4.  Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo.

Authors:  Elizabeth D Hood; Colin F Greineder; Chandra Dodia; Jingyan Han; Clementina Mesaros; Vladimir V Shuvaev; Ian A Blair; Aron B Fisher; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2012-09-06       Impact factor: 9.776

5.  Ferritin Nanocages with Biologically Orthogonal Conjugation for Vascular Targeting and Imaging.

Authors:  Makan Khoshnejad; Colin F Greineder; Katherine W Pulsipher; Carlos H Villa; Burcin Altun; Daniel C Pan; Andrew Tsourkas; Ivan J Dmochowski; Vladimir R Muzykantov
Journal:  Bioconjug Chem       Date:  2018-02-19       Impact factor: 4.774

6.  Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation.

Authors:  Blaine J Zern; Ann-Marie Chacko; Jin Liu; Colin F Greineder; Eric R Blankemeyer; Ravi Radhakrishnan; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2013-02-08       Impact factor: 15.881

Review 7.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

8.  Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies.

Authors:  Thomas D Dziubla; Vladimir V Shuvaev; Nan Kang Hong; Brian J Hawkins; Muniswamy Madesh; Hajime Takano; Eric Simone; Marian T Nakada; Aron Fisher; Steven M Albelda; Vladimir R Muzykantov
Journal:  Biomaterials       Date:  2007-10-24       Impact factor: 12.479

9.  Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.

Authors:  Maria Ansar; Daniel Serrano; Iason Papademetriou; Tridib Kumar Bhowmick; Silvia Muro
Journal:  ACS Nano       Date:  2013-11-20       Impact factor: 15.881

Review 10.  Targeting vascular (endothelial) dysfunction.

Authors:  Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.